[ CAS No. 3703-76-2 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 3703-76-2 * Storage: {[proInfo.prStorage]}

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 3703-76-2 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 3703-76-2 ]

SDS Specification

Alternatived Products of [ 3703-76-2 ]

Product Details of [ 3703-76-2 ]

CAS No. :	3703-76-2	MDL No. :	MFCD00866854
Formula :	C₂₀H₂₄ClNO	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	-
M.W :	329.86	Pubchem ID :	-
Synonyms :

Safety of [ 3703-76-2 ]

Signal Word:	Class:	N/A
Precautionary Statements:	UN#:	N/A
Hazard Statements:	Packing Group:	N/A

Application In Synthesis of [ 3703-76-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 3703-76-2 ]

[ 3703-76-2 ] Synthesis Path-Downstream 1~19

Yield	Reaction Conditions	Operation in experiment
	<2-Chlor-ethyl>-<phenyl-(4-chlor-phenyl)-methyl>-ether, 2 mol Piperidin, Benzol, 100grad;

2
[ 119-56-2 ]
[ 3703-76-2 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 2 steps 1: sulfuric acid / toluene / 5 h / Reflux 2: sodium carbonate / 14 h / 95 °C

Reference： [1]Current Patent Assignee: CHONGQING HENG AN CHEMICAL - CN104327014, 2017, B

3
[ 110-89-4 ]
[ 5321-46-0 ]
[ 3703-76-2 ]

Yield	Reaction Conditions	Operation in experiment
80.7%	With sodium carbonate at 95℃; for 14h;	1 The above 390g oil into 2000mL dry clean three reaction flask, to which was added anhydrous sodium carbonate150g, 180g (2.118mol) of piperidine, heating at 3 / min heating rate to 95 incubated for 14h;After the completion of the reaction, the obtained reaction product was distilled under reduced pressure to recover the piperidine, and the substrate after the piperidine was recovered was cooled to room temperatureTemperature, add 800mL of water to it, then add concentrated hydrochloric acid to adjust the pH value to 2, stir the layers and separate the water layer;The aqueous layer with a concentration of 42% of the caustic soda pH value to 9, with 1000mL ethyl acetate was extracted three times, the combined organicphase;The combined organic phases are dried over anhydrous sodium sulphate and concentrated by filtration to give a light brown oil.The structure of the obtained light brown oil was identified in the present invention and the result shows that the light brown is racemic chlorphenesTing.The present invention weighed racemic clorpsteretin, the result was 393.5g, the calculated yield was 87%;

Reference： [1]Current Patent Assignee: CHONGQING HENG AN CHEMICAL - CN104327014, 2017, B Location in patent: Paragraph 0058; 0117-0122; 0161; 0172; 0187; 0202

4
[ 3703-76-2 ]
[ 132301-89-4 ]

Yield	Reaction Conditions	Operation in experiment
	With di-p-anisoyl-L-tartaric acid In ethanol at 60℃; for 2h;	1 To 1000mL dry clean three reaction flask, followed by the addition of racemic Clopidone 131.8g (0.4mol) and 300mL of ethanol, stir and dissolve, to which 200.8g (0.48mol) of the resolving agent L - (- ) - two pairs of methoxy benzoyl tartaric acid (from Zhejiang Dongyang Chemical Factory) to 4 / min heating rate of the system was heated to 60 insulation 2h;After the completion of the split, the system was naturally cooled double salt precipitation solid, suction filtration, the resulting double salt solid recrystallization with ethanol once, the white double salt.The above white double salt into 1000mL clean reaction flask, to which 400mL of deionized water was added, stirred, neutralized with sodium hydroxide to a pH of 9 to 10, the solution was white double salt solid dissolved completely; the resulting solution with Ethyl acetate extraction three times, the combined organic phase;The resulting organic phase was dried over anhydrous sodium sulfate and filtered to give a pale yellow oil.In the present invention, the above HPLC detection method is used, and the obtained levobisperidone is detected by HPLC analysis. As a resultShown in Figure 1, Figure 1 is obtained in Example 1 of the present invention levobisperidone HPLC profile, as can be seen from Figure 1, L-chlorineThe retention time of Pisidine is about 7.85min, the purity of Levocetirizol obtained in this example is 99.5%

Reference： [1]Current Patent Assignee: CHONGQING HENG AN CHEMICAL - CN104327014, 2017, B Location in patent: Paragraph 0124-0129

5
[ 3703-76-2 ]
[ 84627-04-3 ]
levocloperastine fendizoate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
96.2%	In water; acetone for 2h; Reflux;	1 To 500mL dry clean three reaction flask, followed by the addition of 50g (0.152mol) levopipeline, 53g(0.166mol) Fen to octanoic acid, 300mL of acetone and 50mL of water, stirred, warmed to reflux, the reaction was refluxed for 2h;After the reaction was completed, the reaction system was cooled to room temperature, the resulting reaction product was filtered, washed and dried to give a white solidBody products.

Reference： [1]Current Patent Assignee: CHONGQING HENG AN CHEMICAL - CN104327014, 2017, B Location in patent: Paragraph 0143; 0144; 0161; 0172; 0187; 0202

6
[ 3703-76-2 ]
[ CAS Unavailable ]

Yield	Reaction Conditions	Operation in experiment
78%	Stage #1: Cloperastine With water-d2; lithium carbonate; triisopropylsilanethiol In 1-methyl-pyrrolidin-2-one at 20℃; Irradiation; Stage #2: With hydrogenchloride In 1-methyl-pyrrolidin-2-one

Reference： [1]Loh, Yong Yao; Nagao, Kazunori; Hoover, Andrew J.; Hesk, David; Rivera, Nelo R.; Colletti, Steven L.; Davies, Ian W.; MacMillan, David W. C. [Science, 2017, vol. 358, # 6367, p. 1182 - 1187]

7
[ 3703-76-2 ]
[ CAS Unavailable ]

Yield	Reaction Conditions	Operation in experiment
	With tritium oxide In 1-methyl-pyrrolidin-2-one at 20℃; Irradiation;

8
[ 745783-97-5 ]
[ 3703-76-2 ]
[ 2413385-54-1 ]

Yield	Reaction Conditions	Operation in experiment
88%	With 3,4,7,8-Tetramethyl-o-phenanthrolin; ferrous iodide; sodium t-butanolate In tetrahydrofuran at 120℃; for 12h; Schlenk technique; Glovebox; Inert atmosphere;

Reference： [1]Jia, Jia; Zeng, Xiaoqin; Liu, Zhengli; Zhao, Liang; He, Chun-Yang; Li, Xiao-Fei; Feng, Zhang [Organic Letters, 2020, vol. 22, # 7, p. 2816 - 2821]

9
[ 3703-76-2 ]
[ 2247828-93-7 ]
[ CAS Unavailable ]

Yield	Reaction Conditions	Operation in experiment
78%	In dichloromethane at 70℃; for 3h;	62 Reference Example 62 1-[2-[(4-chlorophenyl)phenyl methoxy]ethyl]-1-[[3-[[(1,1-dimethylethoxy)carbonyl]amino]-2,2-dimethyl-1-oxopropoxy]methyl]piperidinium Iodide 409 mg (1.24 mmol) of cloperastine was added at room temperature to a dichloromethane solution of 443 mg (1.24 mmol) of 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2,2-dimethylpropane acid iodomethyl ester, and the reaction solution was condensed at 70° C. over 1 hour and then stirred at the same temperature for 2 hours. The residue was purified by silica gel column chromatography (2% methanol/chloroform) to obtain 668 mg (78%) of the title compound. 1H-NMR(CDCl3, δ):1.22(611, s), 1.34 (9H, s), 1.77-2.01 (6H, m), 3.25 (2H, d, J=7 Hz), 3.64-3.71 (2H, m), 3.98-3.99 (2H, m), 4.03-4.05 (2H, m), 4.15-4.16 (2H, m), 4.88(1H, br-s), 5.57 (1H, s), 5.59 (1H, d, J=9 Hz), 5.62 (1H, d, J=9 Hz), 7.26-7.36 (9H, m)

Reference： [1]Current Patent Assignee: SEIKAGAKU CORPORATION - US2020/138964, 2020, A1 Location in patent: Paragraph 0366-0368

10
[ 3703-76-2 ]
[ 2137597-06-7 ]
[ 2247829-65-6 ]

Yield	Reaction Conditions	Operation in experiment
85%	In dichloromethane at 70℃; for 1h;	56 Reference Example 56 1-[2-[(4-chlorophenyl)phenyl methoxy]ethyl]-1-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-3-methyl-1-oxobutoxy]methyl]piperidinium Chloride 472 mg (1.43 mmol) of cloperastine was added at room temperature to a dichloromethane solution of 200 mg (0.71 mmol) of 2-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-3-methylbutanoic acid chloromethyl ester, and the reaction solution was condensed at 70° C. over 1 hour and then stirred at the same temperature overnight. The residue was purified by silica gel column chromatography (2→10% methanol/chloroform) to obtain 367 mg (85%) of the title compound. 1H-NMR (CDCl3, δ):0.94 (3H, d, J=7 Hz), 0.97 (3H, d, J=7 Hz), 1.40 (9H, s), 1.77-1.99 (7H, m), 2.59(1H, br-s), 3.29-3.43 (2H, m), 3.65-3.76 (2H, m), 3.95-4.05 (4H, m), 4.16-4.24 (2H, m), 5.07(1H, br-s), 5.48(1H, s), 5.71-5.84 (2H, m), 7.25-7.35 (9H, m)

Reference： [1]Current Patent Assignee: SEIKAGAKU CORPORATION - US2020/138964, 2020, A1 Location in patent: Paragraph 0312-0314

11
[ 3703-76-2 ]
[ 2598024-08-7 ]
[ 2598025-54-6 ]
[ CAS Unavailable ]

Yield	Reaction Conditions	Operation in experiment
80 % ee	With tris(pentafluorophenyl)borate; scandium tris(trifluoromethanesulfonate); 2,6-bis[(4S,6S)-sec-butyl-2-oxazolin-2-yl]pyridine In dichloromethane at 80℃; for 24h; Inert atmosphere; stereoselective reaction;

Reference： [1]Chang, Yejin; Cao, Min; Chan, Jessica Z.; Zhao, Cunyuan; Wang, Yuankai; Yang, Rose; Wasa, Masayuki [Journal of the American Chemical Society, 2021, vol. 143, # 5, p. 2441 - 2455]

12
[ 3703-76-2 ]
[ CAS Unavailable ]
[ 2677770-21-5 ]

Yield	Reaction Conditions	Operation in experiment
59%	With bis(1,5-cyclooctadiene)nickel ⁽⁰⁾; Dimethyl(phenyl)phosphine In toluene at 70℃; for 18h; Schlenk technique; Sealed tube;

Reference： [1]Hitoshio, Kenshiro; Yamagishi, Hiroki; Shimokawa, Jun; Yorimitsu, Hideki [Chemical Communications, 2021, vol. 57, # 56, p. 6867 - 6870]

13
[ 3703-76-2 ]
[ 73183-34-3 ]
[ 2662263-26-3 ]

Yield	Reaction Conditions	Operation in experiment
	With pyridine-4-carbonitrile; potassium phosphate; 2,4,5-tri(9H-carbazol-9-yl)-6-(ethyl(phenyl)amino)isophthalonitrile; N-ethyl-N,N-diisopropylamine In acetonitrile at 20℃; for 24h; Irradiation; Inert atmosphere; Sealed tube;

Reference： [1]Xu, Jinhui; Cao, Jilei; Wu, Xiangyang; Wang, Han; Yang, Xiaona; Tang, Xinxin; Toh, Ren Wei; Zhou, Rong; Yeow, Edwin K. L.; Wu, Jie [Journal of the American Chemical Society, 2021, vol. 143, # 33, p. 13266 - 13273]

14
[ 3703-76-2 ]
[ 132301-89-4 ]
[ 132301-91-8 ]

Yield	Reaction Conditions	Operation in experiment
	With C₄₂H₄₉O₉₈S₂₁^(21-)*21Na⁽¹⁺⁾ In methanol; aq. phosphate buffer Resolution of racemate;	Instrumentation for HPLC The enantiomeric separation was carried out on a Jasco-1500 series HPLC system comprising an isocratic pump,a Rheodyne injector with a fixed loop of 20 μl, and a UVdetector. Borwin software was used for data processing. Theanalysis was conducted under isocratic elution at ambienttemperature. Kromasil C8column (150 × 4.6 mm, 5 μm) wasused for the study. Methanol and 5 mM KH2PO4containing10 mM S-β-CD3 (3.696 g for 200 mL of aqueous phase)at pH 3 (adjusted with 10% OPA) in the ratio of 45:55 v/vwas used as the mobile phase for enantiomeric separation ofCP. The mobile phase was filtered through a 0.45 μm nylon filter and sonicated for 5 min before use. The flow rate wasmaintained at 1 ml/min, and the injection volume was 20 μl.Detection was carried out at 225 nm.

Reference： [1]Mohanraj, Krishnapriya; Deshpande, Krishna; Pathak, Pranav; Joshi, Vishvas; Barton, Stephen [Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2022, vol. 102, # 3-4, p. 279 - 293]

15
[ 3703-76-2 ]
[ 2763620-86-4 ]

Yield	Reaction Conditions	Operation in experiment
	With chlorotris(triphenylphosphine) rhodium (I); (4s,6s)-2,4,5,6-tetra(9H-carbazol-9-yl)isophthalonitrile; deuterium gas In tetrahydrofuran at 20℃; for 12h; Irradiation; Sealed tube;

Reference： [1]Yang, Haifeng; Huang, Zheng; Lehnherr, Dan; Lam, Yu-Hong; Ren, Sumei; Strotman, Neil A. [Journal of the American Chemical Society, 2022, vol. 144, # 11, p. 5010 - 5022]

16
[ 3703-76-2 ]
[ 2412606-40-5 ]
[ CAS Unavailable ]

Yield	Reaction Conditions	Operation in experiment
62%		R.50 1-[2-[(4-chlorophenyl)phenyl methoxy]ethyl]-1-[[[[[3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-methylpropyl]amino]carbonyl]oxy]methyl]piperidinium chloride Reference Example 50 1-[2-[(4-chlorophenyl)phenyl methoxy]ethyl]-1-[[[[[3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-methylpropyl]amino]carbonyl]oxy]methyl]piperidinium chloride 308 mg (0.93 mmol) of cloperastine was added at room temperature to a dichloromethane solution of 262 mg (0.93 mmol) of N-[3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-methylpropyl]carbamic acid chloromethyl ester, and the reaction solution was condensed at 75° C. over 1 hour and then stirred at the same temperature overnight. The residue was purified by silica gel column chromatography (1→10% methanol/chloroform) to obtain 351 mg (62%) of the title compound. 1H-NMR (CDCl3, δ): 0.88 (3H, d, J=7 Hz), 1.42 (9H, s), 1.75-1.90 (7H, m), 2.97-3.18 (4H, m), 3.58-3.76 (4H, m), 3.90-3.92 (2H, m), 4.10-4.17 (2H, m), 5.23 (1H, br-s), 5.46-5.53 (3H, m), 7.25-7.35 (9H, m), 8.26 (1H, br-s)

Reference： [1]Current Patent Assignee: SEIKAGAKU CORPORATION - US2022/257781, 2022, A1

17
[ 3703-76-2 ]
[ CAS Unavailable ]

Yield	Reaction Conditions	Operation in experiment
41%		R.41 1-[2-[(4-chlorophenyl)phenyl methoxy]ethyl]-1-[[[[3-[[(1,1-dimethylethoxy)carbonyl]amino]propoxy]carbonyl]oxy]methyl]piperidinium chloride Reference Example 41 1-[2-[(4-chlorophenyl)phenyl methoxy]ethyl]-1-[[[[3-[[(1,1-dimethylethoxy)carbonyl]amino]propoxy]carbonyl]oxy]methyl]piperidinium chloride 680 mg (2.06 mmol) of cloperastine was added at room temperature to a dichloromethane solution of 368 mg (1.37 mmol) of carbonic acid chloromethyl. 3-[[(1,1-dimethylethoxy)carbonyl]amino]propyl ester, and the reaction solution was condensed at 70'C over 1 hour and then stirred at the same temperature overnight. The residue was purified by silica gel column chromatography (2>10% methanol/chloroform) to obtain 335 mg (41%) of the title compound. 1H-NMR (CDCl3, δ): 1.42 (9H, s), 1.76-1.97 (8H, m), 3.22 (2H, q, J=7 Hz), 3.71-3.78 (2H, m), 3.93-4.05 (4H, m), 4.22-4.26 (4H, m), 4.71 (1H, br-s), 5.46 (1H, s), 5.82 (1H, d, J=12 Hz), 5.84 (1H, d, J=12 Hz), 7.24-7.36 (9H, m)

Reference： [1]Current Patent Assignee: SEIKAGAKU CORPORATION - US2022/257781, 2022, A1

18
[ 432037-37-1 ]
[ 3703-76-2 ]
[ 2412606-55-2 ]

Yield	Reaction Conditions	Operation in experiment
41%	In dichloromethane at 70℃;	41 1-[2-[(4-chlorophenyl)phenylmethoxy]ethyl]-1-[[[[3-[[(1,1-dimethylethoxy)carbonyl]amino]propoxy]carbonyl]oxy]methyl]piperidinium chloride 680 mg (2.06 mmol) of cloperastine was added at room temperature to a dichloromethane solution of 368 mg (1.37 mmol) of carbonic acid chloromethyl. 3-[[(1,1-dimethylethoxy)carbonyl]amino]propyl ester, and the reaction solution was condensed at 70′C over 1 hour and then stirred at the same temperature overnight. The residue was purified by silica gel column chromatography (2>10% methanol/chloroform) to obtain 335 mg (41%) of the title compound. 1H-NMR (CDCl3, δ): 1.42 (9H, s), 1.76-1.97 (8H, m), 3.22 (2H, q, J=7 Hz), 3.71-3.78 (2H, m), 3.93-4.05 (4H, m), 4.22-4.26 (4H, m), 4.71 (1H, br-s), 5.46 (1H, s), 5.82 (1H, d, J=12 Hz), 5.84 (1H, d, J=12 Hz), 7.24-7.36 (9H, m)

Reference： [1]Current Patent Assignee: SEIKAGAKU CORPORATION - US2022/257781, 2022, A1 Location in patent: Paragraph 0272-0274

19
[ 3703-76-2 ]
[ 2412606-40-5 ]
[ CAS Unavailable ]

Yield	Reaction Conditions	Operation in experiment
62%	In dichloromethane at 75℃;	50 1-[2-[(4-chlorophenyl)phenyl methoxy]ethyl]-1-[[[[[3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-methylpropyl]amino]carbonyl]oxy]methyl]piperidinium chloride 308 mg (0.93 mmol) of cloperastine was added at room temperature to a dichloromethane solution of 262 mg (0.93 mmol) of N-[3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-methylpropyl]carbamic acid chloromethyl ester, and the reaction solution was condensed at 75° C. over 1 hour and then stirred at the same temperature overnight. The residue was purified by silica gel column chromatography (1→10% methanol/chloroform) to obtain 351 mg (62%) of the title compound. (0309) 1H-NMR (CDCl3, δ): 0.88 (3H, d, J=7 Hz), 1.42 (9H, s), 1.75-1.90 (7H, m), 2.97-3.18 (4H, m), 3.58-3.76 (4H, m), 3.90-3.92 (2H, m), 4.10-4.17 (2H, m), 5.23 (1H, br-s), 5.46-5.53 (3H, m), 7.25-7.35 (9H, m), 8.26 (1H, br-s)

Reference： [1]Current Patent Assignee: SEIKAGAKU CORPORATION - US2022/257781, 2022, A1 Location in patent: Paragraph 0307-0309

Same Skeleton Products

Related Products

Historical Records

Similar Product of
[ 3703-76-2 ]

A318189[ 14984-68-0 ]

1-(2-((4-Chlorophenyl)(phenyl)methoxy)ethyl)piperidine hydrochloride

Reason: Free-salt

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 3703-76-2 ] {[proInfo.proName]}

Quality Control of [ 3703-76-2 ]

Related Doc. of [ 3703-76-2 ]

Product Details of [ 3703-76-2 ]

Safety of [ 3703-76-2 ]

Application In Synthesis of [ 3703-76-2 ]

[ 3703-76-2 ] Synthesis Path-Downstream 1~19

Similar Product of [ 3703-76-2 ]

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Similar Product of
[ 3703-76-2 ]